TAK-881

**TAK-881** is an investigational facilitated subcutaneous immunoglobulin replacement product developed by Takeda. It comprises plasma-derived human immune globulin 20% and recombinant human hyaluronidase, also known as rHuPH20, which temporarily degrades subcutaneous hyaluronan to improve tissue permeability and enable administration of larger immunoglobulin volumes. It is designed as a next-generation, higher-concentration alternative to HYQVIA, with the potential to reduce infusion volume and duration while maintaining immunoglobulin G exposure and flexible dosing intervals. TAK-881 has shown pharmacokinetic comparability with HYQVIA in a pivotal Phase 2/3 study in primary immunodeficiency disease and is also in Phase 3 evaluation for maintenance treatment of chronic inflammatory demyelinating polyradiculoneuropathy.

Other names

Immune Globulin Subcutaneous Human 20% Solution with Recombinant Human HyaluronidaseSCIG 20% with recombinant human hyaluronidase